三生国健：9月26日召开董事会会议

Group 1 - The core point of the article is that Sanofi (三生国健) announced a board meeting to discuss the cancellation of unvested restricted stock options for 2024, indicating a strategic decision regarding employee compensation and stock management [1] - For the fiscal year 2024, the revenue composition of Sanofi is as follows: 83.02% from pharmaceutical manufacturing, 10.19% from CDMO (Contract Development and Manufacturing Organization) services, 5.54% from licensing, and 1.25% from other businesses, highlighting the company's primary focus on pharmaceutical manufacturing [1] - As of the report, Sanofi's market capitalization stands at 34.5 billion yuan, reflecting its valuation in the market [1]